Authors


Jill Taylot

Latest:

Best Holiday Wishes

I'd like to send warm wishes out to everyone at the beginning of this holiday season. Enjoy a warm meal, savor a bit of time at home with loved ones, and trade hugs with children outside of the pediatric office, where they are actually happy to see you.



Chris Washburn

Latest:

47th Annual Gastroenterology Update: Biologic Therapies for Inflammatory Bowel Disease, Part 2

Ahmed Kandiel, MD, MPH, at the Cleveland Clinic concluded his lecture, "Which Patient/Which Biologic," by reviewing the results of a recently published meta-analysis which examined the risks and benefits of biologic therapy for patients with moderate-to-severe IBD.








Dava Stewart

Latest:

Choriocapillaris Signal Voids Could Characterize AMD

These signal voids could help clinicians more specifically identify AMD in patients.


Robert J. Anderson, MD: From the Department of Medicine, University of Colorado at Denver

Latest:

Anticoagulation for atrial fibrillation-trends in the United States

The use of anticoagulation therapy for atrial fibrillation has slowly increased in the last decade, yet many patients at relatively high risk for thromboembolic events are still not receiving anticoagulants. Patients receiving therapy that is intended to maintain sinus rhythm may be at higher risk for underuse of anticoagulation therapy than those receiving rate control therapies. In addition, the increase in the use of anticoagulation therapy appears to have been particularly notable among patients for whom it may not be indicated and in whom safer, less expensive antithrombotic therapies would suffice.


Luigi Tavazzi, MD

Latest:

The prognostic role of metabolic syndrome after myocardial infarction

We evaluated the prognostic role of metabolic syndrome after myocardial infarction and found that metabolic syndrome correlated with an increased risk of cardiovascular events and death. The risk of developing diabetes decreased with weight loss in patients with metabolic syndrome. These results indicate that a more aggressive approach to the treatment of patients with metabolic syndrome, particularly with regard to changes in lifestyle, would be beneficial.




Matthias E. Pfisterer, MD: From the Department of Cardiology, University Hospital, Basel, Switzerland.

Latest:

Increased risk of major clinical events late after treatment with drug-eluting stents

We compared the incidence of late clinical events after withdrawal of clopidogrel between subjects treated with drug-eluting stents (DES) and those treated with bare-metal stents. Death and myocardial infarction occurred more frequently among DES-treated subjects during the follow-up period. The results of this study indicate that there may be a penalty for the lower rate of restenosis and reinterventions after DES implantation, in particular, an increased rate of late stent thromboses.


From the department of preventive medicine

Latest:

Traditional risk factors across short-, intermediate-, and long-term follow-up in men and women

We found sex differences in the pattern of relative strength when riskfactor associations with death from cardiovascular disease (CVD) were evaluated across different periods of follow-up. In women, an increased risk in CVD-related death was associated with diabetes mellitus and smoking; this risk was most prominent in the early follow-up period. Our finding illustrates that clinicians should employ more intense preventive measures in women who are smokers or have diabetes.




R. Presley Swann, MD

Latest:

Managing Post-Operative Pain with Outpatient Procedures

R. Presley Swann, MD discussed his preference for CPNBs when treating his patient's post-operative pain.



Vidal Essebag, MD, PhD2

Latest:

Amiodarone use and permanent pacing for atrial fibrillation: Are there differences between the sexes?

Among patients with atrial fibrillation, amiodarone (Cordarone, Pacerone) is the most useful drug for the preservation of sinus rhythm.1-3 Although amiodarone carries a well-known risk of potentially serious noncardiac toxicities, perhaps less well recognized is its major cardiovascular side effect of bradycardia.


Michael Greenfield, MD

Latest:

3 Ways to Improve Adherence Among Patients with Diabetes

Medication adherence rates struggle in many conditions and diabetes is among the worst of them. Michael Greenfield, MD, discusses 3 ways for clinicians to improve adherence.


Dominic King

Latest:

6 Keys to Medical Technology Etiquette

How to use all of your medical gadgets without forgetting about the patient in the room.


Ira J. Goldberg, MD is professor of medicine

Latest:

What to measure? Everything is not always better

Conventional measurements of cardiac lipoprotein risk include cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol levels. Low-density lipoprotein (LDL) cholesterol is estimated from these measurements.


Neil Versel

Latest:

The DEA Has Given the Green Light for Electronically Prescribing Controlled Substances

It has been legal to transmit prescriptions for federally designated controlled substances electronically since June 2010. Yet, few of the physicians who already have embraced electronic prescribing have been able to take advantage of the change in the law.





Christina Bratis, MD1

Latest:

Community-acquired MRSA pericarditis

Only 2 cases of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) pericarditis have been reported in the English literature. Over the last 15 years, CA-MRSA has emerged as an increasingly common pathogen that is genetically and epidemiologically different from hospital-acquired MRSA (HA-MRSA).


Inger Nj?lstad, MD, PhD

Latest:

Elevated high-density lipoprotein cholesterol and carotid atherosclerosis

We assessed the relationship between high-density lipoprotein (HDL) cholesterol level and carotid plaque progression in 1952 men and women with preexisting carotid atherosclerosis over a period of 7 years. The HDL cholesterol level was inversely related to plaque growth. The plaques that became more echogenic during follow-up had a lower growth rate compared with those that became more echolucent. These findings suggest that HDL cholesterol stabilizes plaques and counteracts their growth by reducing their lipid content and inflammation.

© 2024 MJH Life Sciences

All rights reserved.